Our Pipeline

In September 2016, the U.S. Food and Drug Administration (FDA) designated TXA709 a Qualified Infectious Disease Product (QIDP), a status that grants TAXIS regulatory incentives including eligibility for fast track designation, priority review, and five additional years of marketing exclusivity. Created under the Generating Antibiotics Incentives Now (GAIN) Act of 2012, the QIDP designation seeks to encourage the development of new antimicrobial drugs to combat the rising threat of multidrug-resistant bacteria.

TAXIS is conducting additional research to validate pre-clinical findings and highlight TXA709 as a weapon in the global fight against antibiotic resistance, an area of significant unmet medical need. The Company plans to complete pre-clinical toxicology studies for both the oral and intravenous (IV) formulations of TXA709 by the end of 2017, and to initiate a Phase I clinical trial in 2018.